A Phase 2 interventional study of FT1 and Placebo in Short Bowel Syndrome and SBS, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Short Bowel Syndrome with a site in China — 4 open to participants now, 6 under way, 2 of them phase 3. Short Bowel Syndrome · China.
Among the 12 studies in Short Bowel Syndrome with a site in China, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 2, and was the 12th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →4 of the 12 studies in Short Bowel Syndrome with a site in China are open now. Recruiting first, the newest first:
Takeda · Sites in China
Ages 1–17
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shandong Qilu Stem Cells Engineering Co., Ltd. · Sites in China
Ages 1 days–28 days
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 27 across the 10 interventional studies, 23 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 7 most frequent:
Chongqing Peg-Bio Biopharm Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Chongqing Peg-Bio Biopharm Co., Ltd. has 3 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Short Bowel Syndrome with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
| NCT07704047Chongqing Peg-Bio Biopharm Co., Ltd.A Clinical Study of FT1 in Patients With Short Bowel Syndrome | 2027-04-15 |
| NCT07691125Changchun GeneScience Pharmaceutical Co., Ltd.Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome | 2027-04-28 |
| NCT07319832TakedaA Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies in Short Bowel Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.
Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS.
Participants will
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, 8 adult SBS patients are treated with once-weekly FT1 or placebo (1:1) for 5 weeks, followed by a washout period of at least 6 weeks, and then the alternate treatment for a further 5 weeks.
Efficacy is evaluated through a 72 hour metabolic balance study conducted at baseline and at the end of each treatment cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FT1 will be administered subcutaneously once a week for 5 weeks during each treatment cycle.
Drug: FT1
FT1 Placebo will be administered subcutaneously once a week for 5 weeks during each treatment cycle.
Drug: Placebo
FT1 treatment, once weekly for 5 weeks
Placebo, once weekly for 5 weeks
Treatment-related Adverse Events
To evaluate the adverse events as characterized by type, frequency, severity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, timing, seriousness, and relationship to study therapy after administration.
Time frame: From the first administration to study completion, appropriately 5 months.
Changes in fecal wet weight from baseline to the end of treatment
The difference in changes in fecal wet weight in the 72-hour metabolic balance study after treatment compared to baseline
Time frame: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
Changes in urine volume from baseline to the end of treatment
The difference in changes in urine volume in the 72-hour metabolic balance study after treatment compared to baseline
Time frame: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t)
Pharmacokinetic parameter
Time frame: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Maximum plasma concentration (Cmax)
Pharmacokinetic parameter
Time frame: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Changes in L-citrulline levels in plasma
Pharmacodynamic parameter
Time frame: From Day 1 of the first cycle to the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
Start is estimated for Aug 2026; primary completion for Apr 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Peg-Bio Biopharm Co., Ltd. →